Upper Tract Urothelial Carcinoma: A Narrative Review of Current Surveillance Strategies for Non-Metastatic Disease

被引:3
|
作者
Klemm, Jakob [1 ,2 ]
Bekku, Kensuke [2 ,3 ]
Abufaraj, Mohammad [2 ,4 ]
Laukhtina, Ekaterina [2 ,5 ]
Matsukawa, Akihiro [2 ,6 ]
Parizi, Mehdi Kardoust [2 ]
Karakiewicz, Pierre I. [7 ]
Shariat, Shahrokh F. [2 ,5 ,8 ,9 ,10 ,11 ,12 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Urol, D-20251 Hamburg, Germany
[2] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, A-1090 Vienna, Austria
[3] Okayama Univ, Dept Urol Dent & Pharmaceut Sci, Grad Sch Med, Okayama 7008525, Japan
[4] Jordan Univ Hosp, Univ Jordan, Dept Special Surg, Div Urol, Amman 11733, Jordan
[5] Sechenov Univ, Inst Urol & Reprod Hlth, Moscow 119991, Russia
[6] Jikei Univ Sch Med, Dept Urol, Tokyo 1058461, Japan
[7] Univ Montreal, Canc Prognost & Hlth Outcomes Unit, Hlth Ctr, Montreal, PQ H2X 3E4, Canada
[8] Al Ahliyya Amman Univ, Hourani Ctr Appl Sci Res, Amman 11942, Jordan
[9] Karl Landsteiner Inst Urol & Androl, A-1090 Vienna, Austria
[10] Weill Cornell Med Coll, Dept Urol, New York, NY 10065 USA
[11] Univ Texas Southwestern, Dept Urol, Dallas, TX 75390 USA
[12] Charles Univ Prague, Fac Med 2, Dept Urol, Prague 25250, Czech Republic
关键词
upper tract urothelial carcinoma; urothelial carcinoma; surveillance; follow-up; UPPER URINARY-TRACT; KIDNEY-SPARING SURGERY; RADICAL NEPHROURETERECTOMY; SEGMENTAL URETERECTOMY; ONCOLOGIC OUTCOMES; INTRAVESICAL RECURRENCE; CONDITIONAL SURVIVAL; RISK STRATIFICATION; RENAL-FUNCTION; ASSOCIATION;
D O I
10.3390/cancers16010044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Upper tract urinary carcinoma (UTUC) is a rare type of cancer affecting the urinary system. Patients with UTUC often undergo surgeries like kidney-sparing surgery or radical nephroureterectomy. However, even after treatment, there remains a risk of the cancer recurring in different parts of the body. This narrative review aims to better understand the frequency and locations of such recurrences, which is crucial for effectively monitoring patients after their initial treatment. Currently, there is limited information on the optimal methods for tracking patients post-surgery, and on how early detection of cancer, before the appearance of symptoms, might improve health outcomes. This article presents the most important current guideline recommendations and elucidates the evidence behind them. Exploring new imaging technologies and improving methods for assessing patient risk, can potentially lead to more personalized and effective monitoring plans in the near future.Abstract Non-metastatic upper urinary tract carcinoma (UTUC) is a comparatively rare condition, typically managed with either kidney-sparing surgery (KSS) or radical nephroureterectomy (RNU). Irrespective of the chosen therapeutic modality, patients with UTUC remain at risk of recurrence in the bladder; in patients treated with KSS, the risk of recurrence is high in the remnant ipsilateral upper tract system but there is a low but existent risk in the contralateral system as well as in the chest and in the abdomen/pelvis. For patients treated with RNU for high-risk UTUC, the risk of recurrence in the chest, abdomen, and pelvis, as well as the contralateral UT, depends on the tumor stage, grade, and nodal status. Hence, implementing a risk-stratified, location-specific follow-up is indicated to ensure timely detection of cancer recurrence. However, there are no data on the type and frequency/schedule of follow-up or on the impact of the recurrence type and site on outcomes; indeed, it is not well known whether imaging-detected asymptomatic recurrences confer a better outcome than recurrences detected due to symptoms/signs. Novel imaging techniques and more precise risk stratification methods based on time-dependent probabilistic events hold significant promise for making a cost-efficient individualized, patient-centered, outcomes-oriented follow-up strategy possible. We show and discuss the follow-up protocols of the major urologic societies.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Endoscopic Ablation of Upper Tract Urothelial Carcinoma: A Report of Two Cases with Long Disease Recurrence-Free Periods
    Yamane, Hiroshi
    Honda, Masashi
    Shimizu, Ryutaro
    Teraoka, Shogo
    Kimura, Yusuke
    Yumioka, Tetsuya
    Iwamoto, Hideto
    Morizane, Shuichi
    Hikita, Katsuya
    Takenaka, Atsushi
    YONAGO ACTA MEDICA, 2022, 65 (02) : 171 - 175
  • [42] The incidence and prevalence of upper tract urothelial carcinoma: a systematic review
    Soualhi, Ahmed
    Rammant, Elke
    George, Gincy
    Russell, Beth
    Enting, Deborah
    Nair, Rajesh
    Van Hemelrijck, Mieke
    Bosco, Cecilia
    BMC UROLOGY, 2021, 21 (01)
  • [43] Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review
    Atiqullah Aziz
    Jakub Dobruch
    Kees Hendricksen
    Luis A. Kluth
    Andrea Necchi
    Aidan Noon
    Michael Rink
    Florian Roghmann
    Roland Seiler
    Paolo Gontero
    Wassim Kassouf
    Shahrokh F. Shariat
    Evanguelos Xylinas
    World Journal of Urology, 2017, 35 : 1401 - 1407
  • [44] Current role of lymphadenectomy in the upper tract urothelial carcinoma
    Alvarez-Maestro, Mario
    Gomez Rivas, Juan
    Alonso y Gregorio, Sergio
    de Castro Guerin, Cristina
    Tabernero Gomez, Angel
    Cisneros Ledo, Jesus
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2016, 69 (04) : 384 - 390
  • [45] Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract
    Sebastiano Nazzani
    Felix Preisser
    Elio Mazzone
    Zhe Tian
    Francesco A. Mistretta
    Shahrokh F. Shariat
    Denis Soulières
    Fred Saad
    Emanuele Montanari
    Stefano Luzzago
    Alberto Briganti
    Luca Carmignani
    Pierre I. Karakiewicz
    World Journal of Urology, 2019, 37 : 1329 - 1337
  • [46] Laboratory Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review
    van Doeveren, Thomas
    van de Werken, Harmen J. G.
    van Riet, Job
    Aben, Katja K. H.
    van Leeuwen, Pim J.
    Zwarthoff, Ellen C.
    Boormans, Joost L.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (06) : 590 - 598
  • [47] Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma
    Li, Xu
    Li, Siming
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Yan, Xieqiao
    Mao, Lili
    Lian, Bin
    Tang, Bixia
    Wang, Xuan
    Bai, Xue
    Zhou, Li
    Kong, Yan
    Dai, Jie
    Guo, Jun
    Sheng, Xinan
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (01) : 75.e1 - 75.e8
  • [48] Clinical Characteristics and Current Status of Treatment for Recurrent Bladder Cancer after Surgeries on Upper Tract Urothelial Carcinoma
    Hu, Xinfeng
    Xue, Yufan
    Zhu, Guodong
    DIAGNOSTICS, 2023, 13 (05)
  • [49] A Novel Risk-based Approach Simulating Oncological Surveillance After Radical Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma
    Shigeta, Keisuke
    Kikuchi, Eiji
    Abe, Takayuki
    Hagiwara, Masayuki
    Ogihara, Koichiro
    Anno, Tadatsugu
    Umeda, Kota
    Baba, Yuto
    Sanjo, Tansei
    Shojo, Kazunori
    Mikami, Shuji
    Mizuno, Ryuichi
    Oya, Mototsugu
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (06): : 756 - 763
  • [50] Treatment strategies for upper tract urothelial carcinoma (UTUC) of a solitary kidney: a single-institutional analysis of 61 cases
    Su, Xiaohong
    Fang, Dong
    Zhang, Lei
    Xiong, Gengyan
    Hao, Han
    Zhao, Guangzhi
    Yang, Kunlin
    Xing, Yunchao
    Li, Xuesong
    Zhou, Liqun
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2016, 48 (10) : 1601 - 1608